VJHemOnc Podcast

VJHemOnc 449 - The current and future role of BTK inhibitors across non-Hodgkin lymphoma subtypes

The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com

00:00

Episodios

23 jul. 2026

16 jul. 2026

10 jul. 2026

30 jun. 2026

22 jun. 2026

15 jun. 2026

29 mayo 2026

22 mayo 2026

15 mayo 2026

08 mayo 2026

01 mayo 2026

24 abr. 2026

16 abr. 2026

09 abr. 2026

02 abr. 2026

27 mar. 2026

20 mar. 2026

27 feb. 2026

20 feb. 2026

06 feb. 2026

30 ene. 2026

22 ene. 2026

16 ene. 2026

09 ene. 2026

18 dic. 2025

12 dic. 2025

27 nov. 2025

20 nov. 2025

14 nov. 2025

07 nov. 2025

31 oct. 2025

16 oct. 2025

29 sep. 2025

19 sep. 2025

12 sep. 2025

04 sep. 2025

20 ago. 2025

15 ago. 2025

08 ago. 2025

01 ago. 2025

29 jul. 2025

18 jul. 2025

14 jul. 2025

04 jul. 2025

30 jun. 2025

20 jun. 2025

14 jun. 2025

05 jun. 2025

30 mayo 2025

VJHemOnc Podcast

Episodios

The current and future role of BTK inhibitors across non-Hodgkin lymphoma subtypes

The diagnosis and management of hematologic malignancies during pregnancy

Hodgkin lymphoma in 2026: frontline strategies, ctDNA, and treatment after relapse

Sequencing BTK inhibitor therapy in CLL: treatment considerations and emerging strategies

Precision medicine in AML: from targeted therapy to transplantation

MPNs in focus: disease progression, risk assessment, and emerging treatments

The evolving role of cellular therapies and T-cell engagers in lymphoma

Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T, and the path to cure

Dual-targeting CAR T-cell therapies in LBCL: efficacy, safety, and bridging therapy

Advances in gene-based therapies for SCD and thalassemia: access, outcomes & innovation

The evolving role of BTK inhibitors in CLL

Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians

The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care

Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies

Myeloid Monthly: breaking news & updates from the classification advancement meeting

How AI is transforming hematologic oncology

MRD in ALL and AML: from prognostic marker to clinical endpoint

Nursing in CAR-T & cellular therapy: updates and insights from the EBMT-EHA CAR T-cell Meeting 2026

Recent BTK inhibitor trial updates across non-Hodgkin lymphoma subtypes

ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD

Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies

Managing and preventing differentiation syndrome in APL

Top ASH 2025 NHL updates: novel CAR T-cell therapies, fixed-duration strategies, evolving frontline approaches, & more

Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T, trispecific antibodies, and more!

Top CLL updates from ASH 2025: novel BTKi monotherapy and combination approaches, BTK degraders, & more

Top updates in MDS from ASH 2025: key trial updates and debated topics

Sickle cell disease management: navigating the transition from pediatric to adult care, managing VOCs, & more

Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges

The value and utility of MRD in the management of adults with newly-diagnosed AML

Updates from iwHRMM: targeted and immune-related therapies and mechanisms of resistance

Advances in immunotherapy for NHL: updates from iwNHL 2025

Reviewing recent guideline updates on the risk stratification and treatment of AML

The management of CLL in resource-limited settings: guideline development and ongoing projects

The multi-disciplinary team in CAR-T therapy: insights from a nurse, a neurologist, and a palliative care specialist

Understanding financial and time toxicity in cancer care: advice for community oncologists

Listener Q&A special: expert insights on CLL, myeloma, and lymphoma

Novel strategies and advances in the management and classification of MDS: insights from iwMDS 2025

Advances in Waldenström’s macroglobulinemia: significance of genetic alterations, current treatment strategies, & ongoing trials

FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD

Extramedullary disease in multiple myeloma: biology, management strategies, & the RedirecTT-1 trial

iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more

Managing CNS lymphoma: expert insights and updates from ICML 2025

iwMDS wrap-up: translating research into practice to optimize patient care

Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification

Treating elderly or unfit patients with AML: current approach and future directions

Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!

CHIP & CCUS: advances in understanding and should we treat these precursor conditions?

Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain

IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more

Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease